- Report
- June 2022
- 292 Pages
Global
From €2218EUR$2,500USD£1,936GBP
- Report
- April 2022
- 64 Pages
Global
From €3105EUR$3,500USD£2,710GBP
- Report
- April 2022
- 37 Pages
Global
From €1774EUR$2,000USD£1,549GBP
- Report
- February 2022
- 50 Pages
Global
From €3105EUR$3,500USD£2,710GBP
- Report
- February 2022
- 74 Pages
Global
From €1774EUR$2,000USD£1,549GBP
- Drug Pipelines
- March 2021
Global
From €1774EUR$2,000USD£1,549GBP
- Report
- October 2024
- 198 Pages
Global
From €2218EUR$2,500USD£1,936GBP
- Report
- August 2024
- 180 Pages
Global
From €2218EUR$2,500USD£1,936GBP
- Report
- August 2022
- 308 Pages
Global
From €3194EUR$3,600USD£2,788GBP
- Report
- September 2025
- 150 Pages
China
From €3416EUR$3,850USD£2,981GBP
- Report
- September 2025
- 150 Pages
Canada
From €3416EUR$3,850USD£2,981GBP
- Report
- February 2024
- 188 Pages
Global
From €3992EUR$4,500USD£3,485GBP
- Report
- April 2024
- 123 Pages
Global
From €3504EUR$3,950USD£3,059GBP
- Report
- April 2023
- 147 Pages
Global
From €4391EUR$4,949USD£3,833GBP
- Report
- June 2024
- 116 Pages
Global
From €3500EUR$4,226USD£3,162GBP
- Report
- December 2024
- 48 Pages
Global
From €439EUR$495USD£383GBP
- Report
- August 2024
- 54 Pages
Global
From €1730EUR$1,950USD£1,510GBP
- Drug Pipelines
- February 2024
- 29 Pages
Global
From €439EUR$495USD£383GBP
- Report
- January 2024
- 283 Pages
Global
€4431EUR$4,995USD£3,868GBP
- Training
- October 2021
- 1 Day
Latin America
From €1152EUR$1,299USD£1,006GBP

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them.
The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives.
Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more